Virus News and Research

Latest Virus News and Research

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented preliminary data from a randomized dose-ranging Phase 2 trial of JX-594 in patients with advanced liver cancer showing a benefit in overall survival for the high dose group.

20 May 2011

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

20 May 2011

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

For my money, the most interesting thing about Mitt Romney's health-care speech last week wasn't his struggle to defend Romneycare and distance it from Obamacare, but the largely hostile reception of the speech from the right.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

CSL welcomes historic pandemic agreement

CSL Biotherapies welcomed news overnight of a decision by the World Health Assembly to adopt the Pandemic Influenza Preparedness Framework for the Sharing of Influenza Viruses and Access to Vaccines and Other Benefits. The Framework is the culmination of several years work by a dedicated working group of the World Health Organisation (WHO) and paves the way for greater global collaboration between public and private stakeholders in preparing the world for possible future influenza pandemics.

19 May 2011

Humanized BLT mice help prevent HIV/AIDS transmission

The more than 2.7 million new HIV infections recorded per year leave little doubt that the HIV/AIDS epidemic continues to spread globally. That's why there's the need for safe, inexpensive and effective drugs to successfully block HIV transmission.

19 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

Epstein-Barr virus might cause multiple sclerosis, study confirms

The Epstein-Barr (EVB) virus -belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus- is one of the environmental factors that might cause multiple sclerosis, a condition affecting the central nervous system, which causes are unknown.

18 May 2011

New experimental vaccine prevents infection of horses with deadly Hendra virus

CSIRO scientists have shown that a new experimental vaccine helps to protect horses against the deadly Hendra virus. Dr Deborah Middleton from CSIRO's Australian Animal Health Laboratory (AAHL) will announce the successful progress to develop the vaccine at the Australian Veterinary Association conference in Adelaide today.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Bill Gates urges wiser vaccine coverage worldwide to save millions

Tuesday this week, Bill Gates called for strengthened immunization programs against infectious diseases to save 4 million lives by 2015 and 10 million lives by 2020, calling it the best possible investment in global health. He was addressing the annual assembly of the World Health Organization (WHO) in Geneva, attended by health ministers from the U.N. agency's 193 member states.

17 May 2011

Decision on destroying last of the stored small pox virus samples

Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.

17 May 2011

World Health Assembly begins in Geneva

As the 64th World Health Assembly gets underway in Geneva, the body will consider "an array of subjects pertaining to reforms of the organisation and its financing, vaccines, fake medicines, and influenza pandemic preparedness, as well as communicable and non-communicable diseases," Intellectual Property Watch reports.

17 May 2011

Novel topically-applied molecular microbicide protects women against HIV infection

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.

17 May 2011

Pediatric researchers find potential tools for controlling cytokine storm

By analyzing complex interactions of the immune system in an animal study, pediatric researchers have found potential tools for controlling a life-threatening condition called a cytokine storm that may strike children who have juvenile arthritis and other autoimmune diseases.

17 May 2011

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Researchers at Sandia National Laboratories have developed a super-resolution microscopy technique that is answering long-held questions about exactly how and why a cell's defenses fail against some invaders, such as plague, while successfully fending off others like E.coli.

17 May 2011

Viewpoints: Ryan on 'shared scarcity'; Romney fallout; Baltimore's ambitious health plan

Too many in Washington remain fixated on the next election, at the expense of the next generation. But there is a hidden cost to the shared scarcity mentality — a cost measured in lost prosperity and lost freedom. We face a choice between two futures. We can continue to go down the path toward shared scarcity, or we can choose the path of renewed prosperity.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Hendra virus vaccine to be released soon

According to CSIRO’s early success with testing, the Hendra virus vaccine for horses could be available as early as next year. Hendra virus affects horses and is contracted through contact with flying foxes.

16 May 2011

Virus News and Research

Latest Virus News and Research

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Jennerex presents positive preliminary data from JX-594 Phase 2 trial for advanced liver cancer

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CSL welcomes historic pandemic agreement

Humanized BLT mice help prevent HIV/AIDS transmission

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Epstein-Barr virus might cause multiple sclerosis, study confirms

New experimental vaccine prevents infection of horses with deadly Hendra virus

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Bill Gates urges wiser vaccine coverage worldwide to save millions

Decision on destroying last of the stored small pox virus samples

World Health Assembly begins in Geneva

Novel topically-applied molecular microbicide protects women against HIV infection

Pediatric researchers find potential tools for controlling cytokine storm

Super-resolution microscopy technique reveals how and why cell's defenses fail against plague

Viewpoints: Ryan on 'shared scarcity'; Romney fallout; Baltimore's ambitious health plan

FDA nod for hepatitis C drug

Hendra virus vaccine to be released soon

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Virus News and Research

Latest Virus News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in